No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715)
Background Chemotherapy-induced peripheral neuropathy ( CIPN ) is a common and disabling side effect of taxanes . Acetyl-L-carnitine ( ALC ) was unexpectedly found to increase CIPN in a r and omized trial . We investigated the long-term patterns of CIPN among patients in this trial . Methods S0715 was a r and omized , double-blind , multicenter trial comparing ALC ( 1000 mg three times a day ) with placebo for 24 weeks in women undergoing adjuvant taxane-based chemotherapy for breast cancer .  CIPN was measured by the 11-item neurotoxicity ( NTX ) component of the FACT-Taxane scale at weeks 12 , 24 , 36 , 52 , and 104 . We examined NTX scores over two years using linear mixed models for longitudinal data . Individual time points were examined using linear regression . Regression analyses included stratification factors and the baseline score as covariates . All statistical tests were two-sided . Results Four-hundred nine subjects were eligible for evaluation . Patients receiving ALC  had a statistically significantly ( P = .01 ) greater reduction in NTX scores ( worse CIPN ) of -1.39 points ( 95 % confidence interval [ CI ] = -2.48 to -0.30 ) than the placebo group . These differences were particularly evident at weeks 24 ( -1.68 , 95 % CI = -3.02 to -0.33 ) , 36 ( -1.37 , 95 % CI = -2.69 to -0.04 ) , and 52 ( -1.83 , 95 % CI = -3.35 to -0.32 ) . At 104 weeks , 39.5 % on the ALC arm and 34.4 % on the placebo arm reported a five-point ( 10 % ) decrease from baseline . For both treatment groups , 104-week NTX scores were statistically significantly different compared with baseline ( P < .001 ) . Conclusions For both groups , NTX scores were reduced from baseline and remained persistently low . Twenty-four weeks of ALC therapy result ed in statistically significantly worse CIPN over two years . Underst and ing the mechanism of this persistent effect may inform prevention and treatment strategies . Until then , the potential efficacy and harms of commonly used supplements should be rigorously studied
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .